Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction

Journal of the American College of Cardiology

Volumn 34, Issue 4, 1999, Pages 983-988

  Soejima, Hirofumi ^a   Ogawa, Hisao ^a   Yasue, Hirofumi ^a   Kaikita, Koichi ^a   Takazoe, Keiji ^a   Nishiyama, Koichi ^a   Misumi, Kenji ^a   Miyamoto, Shinzo ^a   Yoshimura, Michihiro ^a   Kugiyama, Kiyotaka ^a   Nakamura, Shin ^b   Tsuji, Ichiro ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOAGULANT; PROTEIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; CHEMOKINE CCL2; DOUBLE-BLIND METHOD; ENALAPRIL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; MYOCARDIAL INFARCTION; THROMBOPLASTIN;

EID: 0033213675     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00318-6     Document Type: Article

References (44)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
4. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
5. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79.
6. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis 1993;4:281-92.
7. Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995;73:10-3.
8. Suefuji H, Ogawa H, Yasue H, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253-9.
9. Misumi K, Ogawa H, Yasue H, et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998;81:21-6.
10. Soejima H, Ogawa H, Yasue H, et al. Effect of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am J Cardiol 1996;78:336-40.
11. Annex BH, Denning SM, Chnnon KM, et al. Differential expression of tissue factor protein in atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-22.
12. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997;17:2232-7.
13. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implication for plaque rupture. Circulation 1994;90:775-8.
14. Robinson EA, Yoshimura T, Leonard EJ, et al. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc Natl Acad Sci USA 1989;86:1850-4.
15. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Ann Rev Immunol 1991;9:617-48.
16. Nishiyama K, Ogawa H, Yasue H, et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 1998;62:710-2.
17. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645-51.
18. Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989;72:391-6.
19. Nishiyama K, Ogawa H, Yasue H, et al. Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina. Thromb Res 1998;89:137-46.
20. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1988;47:1-9.
21. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-7.
22. Soejima H, Ogawa H, Yasue H, et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997;20:441-5.
23. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
24. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
25. Ardissino D, Merlini PA, Arëns R, et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-71.
26. Taubman MB, Marmur JD, Rosenfield CL, et al. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. J Clin Invest 1993;91:547-52.
27. Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-95.
28. Nakamura S, Kamikubo Y. Clinical significance and use of tissue factor assay for blood samples. Jpn J Clin Hematol 1995;36:263-6 (in Japanese).
29. Baja MS, Kuppuswamy MN, Saito H, et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-73.
30. Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992;111:681-7.
31. Sandset PM, Abildgaad U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-13.
32. Novotny WF, Palmier M, Wun TC, et al. Purification and properties of heparin releasable lipoprotein associated inhibitor. Blood 1991;78:394-400.
33. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990;59:651-6.
34. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991;2:713-21.
35. Kokawa T, Enjyoji K, Kumeda K, et al. Measurement of the free form of TFPI antigen in hyperlipidemia: relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996;16:802-8.
36. Caplice NM, Muesuke CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998;98:1051-7.
37. Oltrona L, Speidel CM, Recchia D, et al. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-52.
38. Falciani M, Gori AM, Fedi S, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998;79:495-9.
39. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-l/JE. Am J Pathol 1990;136:1229-33.
40. Badolato R, Ponzi AN, Millesimo M, et al. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 1997;90:2804-9.
41. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-κB and expression of monocyte chemoattractant protem-1 in human aortic smooth muscle cells. Circulation 1997;96:2361-7.
42. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996;83:307-20.
43. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29:419-23.
44. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.